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Abstract  
 
Objective: Lower levels of anabolic hormones in older age are well documented. Several 
studies suggested that low insulin-like growth factor I (IGF-I) or testosterone levels were 
related to increased mortality. The aim of the present study was to investigate the combined 
influence of low IGF-I and low testosterone on all-cause mortality in men.  
 
Methods and results: From two German prospective cohort studies, the DETECT study and 
SHIP, 3942 men were available for analyses. During 21,838 person-years of follow-up, 8.4% 
(n = 330) of men died. Cox model analyses with age as timescale and adjusted for potential 
confounders revealed that men with levels below the 10th percentile of at least one hormone 
[hazard ratio (HR) 1.38 (95% confidence-interval (CI) 1.06–1.78), p = 0.02] and two 
hormones [HR 2.88 (95% CI 1.32–6.29), p < 0.01] showed a higher risk of all-cause mortality 
compared to men with non-low hormones. The associations became non-significant by using 
the 20th percentile as cut-off showing that the specificity increased with lower cut-offs for 
decreased hormone levels. The inclusion of both IGF-I and total testosterone in a mortality 
prediction model with common risk factors resulted in a significant integrated discrimination 
improvement of 0.5% (95% CI 0.3–0.7%, p = 0.03).  
 
Conclusions: Our results prove that multiple anabolic deficiencies have a higher impact on 
mortality than a single anabolic deficiency and suggest that assessment of more than one 
anabolic hormone as a biomarker improve the prediction of all-cause mortality.   
 
Keywords: IGF-I Testosterone Mortality Study of Health in Pomerania (SHIP) DETECT   
 
1. Introduction  
 
Insulin-like growth factor I (IGF-I) and total testosterone are anabolic hormones involved in 
the aging process with a strong age-dependent decline in their concentration [1,2]. IGF-I, as 
the main mediator of the growth hormone actions, is involved in cell replication and 
proliferation, protein synthesis, as well as glucose and lipid metabolism [3]. Low IGF-I levels 
have recently been related to a broad range of morbidities including chronic obstructive 
pulmonary disease [3], osteoporosis [3], metabolic syndrome (MetS), or diabetes mellitus 
[4,5], as well as overall mortality [6]. Testosterone represents the principal male sex hormone 
and is linked to the regulation of e.g. fertility, libido, muscle mass and glucose metabolism 
[7]. Low total testosterone levels have been associated with hypertension [7], insulin 
resistance [8], the MetS, and type 2 diabetes [9].  
 
In addition to the associations with major co-morbidities, we recently have demonstrated that 
low levels of IGF-I [6] and total testosterone [10] were directly associated with increased risk 
of mortality in a population-based samples of men. In particular, men with either low IGF-I or 
total testosterone levels had an almost two-fold higher risk of all-cause mortality.  
 
The impact of multiple low serum hormone concentrations, including IGF-I, total testosterone 
and dehydroepiandrosterone sulphate on mortality was investigated in two previous studies 
[11,12]. The InCHIANTI study [12] as well as a Polish study in men with chronic heart 
failure [11] reported that the risk of mortality constantly increases with the number of 
deficient hormones. However, both studies were limited by relatively small study populations 
of 410 [12] or 208 [11] men, respectively, and by a narrow age-range. Furthermore, these 
studies suggested that a combination of more than one hormone might be superior in the 
prediction of mortality. However, the quantification of the improvement in risk prediction by 
the combined biomarkers as one of the key questions has not been answered satisfactorily.  
 
Therefore the objective of the present study was to verify the previously described association 
between the combination of low hormone levels and all-cause mortality based on IGF-I and 
total testosterone levels in a population of 4092 men aged 18–91 years from two studies. 
Furthermore, we examined whether the prediction of mortality on the basis of a model 
containing hormone levels is superior to a model with known risk factors.  
 
 
2. Materials and methods  
 
2.1. Design and subjects  
 
DETECT (Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for 
Commitment of Treatment) is a large, multistage, and nationally representative study in 
Germany [13]. On 16th and 18th September 2003, 3188 GPs completed a standardized 
assessment of the diagnostic and therapeutic profile of 55,518 unselected consecutive patients 
(59% women and 41% men; over 17 years). These physicians were successfully recruited, 
meeting the recruitment criteria, namely enrolment from signature, completion of pre-study 
questionnaire, willingness to adhere to the complex laboratory and follow-up procedures. This 
constitutes a total initial response rate of 60.2% for the physicians. Further adjustments for 
non-response, regional distribution, and attrition were performed. Out of a total of N = 55,518 
eligible patients at the target days, a random subsample of N = 7519 in 851 primary care 
settings additionally attended a standardized laboratory screening program and were part of 
the prospective component of DETECT. Of these patients, 6826 (2782 men and 4044 women) 
participated in a 1-year or 4-year follow-up which were conducted between September and 
December 2004 or 2007. It results in a patient response rate of 90.8%. The study was 
approved by the ethics committee of the Technical University of Dresden (AZ: 
EK149092003; date: September 16th, 2003). All patients gave written informed consent. Of 
the 2782 men, seven men were excluded due to missing information on time of death. 
Furthermore, 529 patients with missing data for IGF-I or total testosterone and 178 patients 
with missing data for used confounders were also excluded. Valid data were available in 2068 
men. No differences regarding age, physical activity, waist- to-height ratio (WHtR), diabetes, 
and increased blood pressure were found between excluded men (n = 714) and men 
participated in the present study.  
 
SHIP (Study of Health in Pomerania) is a longitudinal population- based cohort study in West 
Pomerania, a region in the northeast of Germany [14,15]. The total population of West 
Pomerania selected for SHIP comprised 212,157 inhabitants. A two-stage cluster sampling 
method adopted from the WHO MONICA Project Augsburg, Germany yielded 12 five-year 
age strata (20–79 years) for both genders, each including 292 individuals [16]. The sampling 
was performed from population registries, where all German citizens are registered. Data 
collection started in October 1997 and was finished in March 2001. The net sample (after 
exclusion of migrated or deceased persons) comprised 6267 eligible subjects. All subjects 
received a maximum of three written invitations. In cases of non-response, letters were 
followed by several phone calls or by home visits if contact by phone was not possible. 
Finally, 2116 men and 2192 women (response proportion 69%) participated. All participants 
gave written informed consent. The study conformed to the principles of the Declaration of 
Helsinki as reflected by an a priori approval of the Ethics Committee of the University of 
Greifswald. Of the 2116 male participants 125 subjects with missing data for IGF-I or total 
testosterone and 117 patients with missing data for used confounders were excluded. Valid 
data including mortality follow-up were available in 1911 men. Excluded men (n = 242) were 
on average 4 years younger than men included in the analyses. However, no differences 
regarding the age-adjusted proportions/mean of smoking, physical activity, diabetes, 
increased blood pressure or WHtR were found.  
 
2.2. Instruments and measurements  
 
Information on age, sex, socio-demographic characteristics, and medical histories were 
assessed by standardised interviews and medical records by the primary care physicians in 
DETECT and by standardised computer-assisted personal interviews in SHIP. In both studies, 
physicians and study nurses were advised to measure weight, height, blood pressure, and 
waist circumference according to written, standardized instructions given in a manual. 
Smoking was categorised into smokers and non-smokers. Subjects who participated in 
physical training during summer or winter for at least two hour a week were classified as 
being physically active. A systolic and diastolic blood pressures of >140 and >90 mmHg, 
respectively, were considered increased. Diabetes mellitus was defined as history of diabetes 
as reported by patients or physicians in DETECT and SHIP, respectively, intake of oral 
antidiabetic drugs or insulin, or hemoglobin A1c (HbA1c) levels P6.5%. For both studies, we 
defined liver disease as physician’s or self-reported diagnosis of liver disease or aspartate-
amino-transferase or alanin-aminotransferase > population mean + 2  standard deviation. 
Kidney failure was assumed if the estimated glomerular filtration rate (GFR) using the 
Modification of Diet in Renal Disease (MDRD) formula was <30 ml/min [17]. Missing values 
in categorical variables were treated as separate group.  
 
In DETECT, blood samples were collected and shipped by courier at room temperature within 
24 h to the central laboratory. Blood samples were taken either fasting or non-fasting and 
fasting state was recorded. Upon arrival in the central laboratory, the samples were 
centrifuged immediately and serum and plasma was stored at -20 °C until further processing. 
In SHIP non-fasting blood samples were taken between 07:00 a.m. and 04:00 p.m., analysed 
immediately for routine clinical chemistry parameters and stored at -80 °C for IGF-I and 
testosterone analyses. In both studies IGFI was determined with an automated 
chemiluminescence system (Nichols Institute Diagnostics, San Clemente, CA, USA). The 
analytical sensitivity was 6 ng/ml. In SHIP, total testosterone levels were measured using 
competitive chemiluminescent enzyme immunoassays on an Immulite 2500 analyzer 
(Siemens Immulite 2500 DHEA-SO4, ref. L5KDS, lot 106; and Siemens Immulite 2500 Total 
Testosterone, ref. L5KTW, lot 110; Siemens Healthcare Diagnostics GmbH, Eschborn, 
Germany). The analytical sensitivity was 0.5 nmol/l. In DETECT, total testosterone was 
determined with an electrochemiluminescence immunoassay (Modular analytics, Roche 
Diagnostics, Mannheim, Germany). The analytical sensitivity was 0.069 nmol/l. Reagents and 
secondary standard were used as recommended by the manufacturer. Separately in DETECT 
and SHIP, low levels of IGF-I and total testosterone were defined according to the 10th, 15th, 
or 20th percentile in every 5-years age-group (Table A.1).  
 
2.3. Statistical analysis  
 
Categorical data were expressed as percentages; continuous data were expressed as mean 
(standard deviation). Bivariate statistic was performed with χ2 test for categorical variables 
and Mann– Whitney-U-test for continuous distributions. Multivariable Cox proportional 
hazard regression models with age as timescale were run to assess the associations between 
low hormone levels and all cause mortality. The full models were adjusted for WHtR, 
smoking, physical activity, diabetes, liver diseases, increased blood pressure, and high-
sensitive C-reactive protein. A sensitivity analysis was performed after the exclusion of men 
with a GFR <30 ml/min. The model assumption for the Cox proportional hazards regression 
model was checked with Schoenfeld residuals and log of the negative log of survival plots. 
Hazard ratios (HR) with 95% confidence intervals (CI) were calculated. Furthermore, we 
estimated the integrated discrimination improvement (IDI) to examine whether the prediction 
on the basis of a model without IGF-I or testosterone was significantly improved after 
inclusion of both hormones as continuous parameters [18]. In contrast to the net 
reclassification improvement which needs a priori meaningful predicted risk categories, the 
integrated discrimination improvement is based on continuous differences in the predicted 
risk from new and old models. IDI were obtained with logistic regression models that 
examined deaths through 4 years of follow-up, which was available for 3336 participants. 
Moreover, the corresponding areas under the curve (AUC) were calculated and compared as 
well as receiver-operating-characteristic (ROC) curves were plotted for model with and 
without IGF-I and testosterone. A value of p < 0.05 was considered statistically significant. 
Statistical analyses were performed with SAS 9.1 and 9.2 (SAS Institute Inc., Cary, NC, 
USA) and Stata 9 (Stata Corporation, College Station, TX).  
 
 
3. Results  
 
3.1. General characteristics  
 
Comparisons regarding general baseline characteristics are presented in Table 1. Men with 
one or two low hormone levels had a higher WHtR, were less physically active and more 
often affected by diabetes mellitus and liver diseases compared to men with non-low IGF-I 
and total testosterone levels, respectively. No differences in smoking habits were apparent 
between the different groups.  
 
3.2. Association of IGF-I and total testosterone levels to all-cause mortality  
 
During the 21,838 person-years (SHIP 15,299 person-years, DETECT 6538 person-years) of 
follow-up 8.4% (n = 330) of men died. The crude mortality rate ratios are given in Table 2. 
Men with two hormones involved had, independently of the used categorization, higher crude 
rate ratios. Results of univariate Kaplan–Meier survival analysis (Fig. 1) also revealed that the 
decrease in cumulative survival was more evident in men with one (p < 0.01) or two (p < 
0.01–0.05) hormones with low levels compared to men with two non-low hormones.  
 
These findings were confirmed by multivariable Cox regression analyses adjusted for WHtR, 
smoking, and physical activity. Men with one or both hormones below the 10th or 15th 
percentile had higher risks of all-cause mortality compared to men with two non-low 
hormones (Table 3). Furthermore, the mortality risk is higher for 2 low hormones compared 
to 1 low hormone which implies a dose–response relation. The additional inclusion of 
diabetes, liver disease, increased blood pressure, and high-sensitive C-reactive protein as 
confounders did not affect these results for the 10th percentile. However, in analyse using the 
15th percentile as cut-off, only men with 2 low hormones had still a significant higher 
mortality risk. Therefore, the risk estimates and thus the specificity increased with lower cut-
offs to define low levels of IGF-I and total testosterone.  
 
Further factors which were significantly related to all-cause mortality (model with 10th 
percentile as cut-off for testosterone and IGF-I) were smoking [HR 2.41 (95% CI 1.83–3.17), 
p < 0.01], diabetes [HR 1.45 (95% CI 1.14–1.84), p < 0.01], liver disease [HR 2.26 (95% CI 
1.52–3.38), p < 0.01], increased blood pressure [HR 0.79 (95% CI 0.63–0.99), p = 0.04], and 
high-sensitive C-reactive protein [per 10 mg/l HR 1.16 (95% CI 1.08–1.24), p < 0.01].    
 
The exclusion of men with a GFR <30 ml/min [n = 23; one hormone <10th percentile: HR 
1.41 (95% CI 1.09–1.82), p = 0.01; two hormones <10th percentile: HR 2.65 (95% CI 1.14–
6.18), p = 0.02], men who died within the first year of follow-up [n = 34; one hormone <10th 
percentile: HR 1.42 (95% CI 1.08–1.86), p = 0.01; two hormones <10th percentile: HR 3.07 
(95% CI 1.34–7.03), p < 0.01], or SHIP men who received androgen therapy (testosterone or 
other androgens), GH or any kind of anti-androgen therapy [n = 4; one hormone <10th 
percentile: HR 1.38 (95% CI 1.06–1.78), p = 0.02; two hormones <10th percentile: HR 2.88 
(95% CI 1.32–6.29), p < 0.01] did not change the results substantially. Moreover, we 
performed an additional analyse in the subgroup of men older than 60 years (n = 1805). Also 
these analyses showed that men with one [HR 1.41 (95% CI 1.06–1.86), p = 0.02] or two 
[<10th percentile: HR 2.90 (95% CI 1.24–6.79), p = 0.01] low hormone levels had a higher 
mortality risk.  
 
After the inclusion of IGF-I and total testosterone to the standard model (with age, smoking, 
systolic blood pressure, diabetes, WHtR, total cholesterol, and HDL cholesterol as predictors), 
the discrimination slope increased from 9.42% to 9.92%; resulting in an absolute IDI of 0.5% 
(95% CI 0.3–0.7%, p = 0.03) and a relative IDI of 5.3%. AUC for the standard model was 
0.809 and slightly increased to 0.811 after the inclusion of IGF-I and total testosterone as 
additional predictors (p = 0.52).  
 
 
4. Discussion  
 
In the present study we revealed that the mortality risk in adult men successively increases 
with the combination of low IGF-I and testosterone levels, independent of age and major 
confounders. This is in good agreement with previous results of the InCHIANTI study, a 
cohort study that investigated the relation of low levels of IGF-I, bioavailable testosterone, 
and dehydroepiandrosterone sulfate with mortality in 410 men 65 years or older [12]. In 
contrast to previous studies including the SHIP cohort [6,10], which revealed a higher all-
cause mortality in men with low IGF-I [6,19,20] or low total testosterone levels [10,21,22], in 
the InCHIANTI study low IGF-I or low bioavailable testosterone as single hormones were not 
related to mortality [12]. Small patient and event numbers (InCHIANTI 126 deaths vs. SHIP 
359 deaths) might be explain the different findings.  
 
Furthermore, the cut-off to define low free or total testosterone levels plays an important role 
as shown in Fig. 1. The InCHIANTI study used a higher value of 2.4 nmol/l (lowest quartile) 
to define low bioavailable testosterone levels as compared with current guidelines [23]. This 
cut-off might be too unspecific to detect an association between low testosterone levels and 
mortality as we show in our study population for the 20th percentile. A further study in 208 
men with chronic heart failure, also investigating IGF-I and testosterone, similarly revealed 
decreasing survival rates with an increase in the number of low hormones [11]. Furthermore, 
each single hormone level was inversely related to mortality in this study. In contrast to 
former studies our present study population consisted of men who were not selected by age or 
according to a specific disease with per se increased mortality risk. Our cohort covered a 
broader age-range and included over 4000 men with 359 cases of death [11,12].  
 
Changes in IGF-I and testosterone levels due to the aging process are well documented. Both 
IGF-I and total testosterone levels significantly decline with age and thus it seems 
consequential that lower hormone levels are related to increased morbidity [3,24]. Whether 
IGF-I or total testosterone levels directly influence mortality, or represent biomarkers of 
underlying morbidity is still subject of debate. However, the concept that low levels of 
hormones may play an independent causal role in longevity, is not surprising. Multisystemic 
disorders that are widely prevalent in aging subjects, such as the metabolic syndrome, frailty 
syndrome, and chronic heart failure, are more likely associated with multiple hormonal 
dysregulation rather than a single hormonal derangement [11,25]. There is increasing 
evidence that aging or subclinical diseases are associated with a decline in hormones and 
increase in catabolic hormones [26]. Therefore, hormonal deficiency might be a surrogate 
parameter of disease severity, especially in men. In face of the present findings, it was beyond 
the scope of our study to analyze if the association of hormonal dysregulation with increased 
mortality is also present for other non-anabolic hormones such as, for example, thyroid 
hormone levels. Even though, an analysis of the SHIP cohort revealed no independent 
association of thyrotropin levels with mortality [27], further studies are needed for a 
conclusive answer. In face of the fact that we used age-specific low hormone levels it is 
arguable to break the problem only down to the aging process. One possible, but clearly 
theoretical, explanation might be a complex interaction between genetic background, 
individual risk behaviour and hormone regulation. Several genome-wide association studies 
showed that genetic variants of the fat mass- and obesity-associated gene (FTO) are related to 
obesity [28,29], which in turn represents a major cause for low testosterone levels in men. 
Furthermore, another investigation on the SHIP collective revealed that the FTO risk alleles 
were associated with lower IGF-I levels independently of obesity [30]. Moreover, obesity and 
the FTO gene are associated with an abnormal glucose metabolism as well as cardiovascular 
disease in men and therefore, are risk factors for mortality [31]. All these facts contribute to 
the complex interplay between hormone regulation and mortality. However the present study 
has, due to its epidemiological design, not the ability to clarify specific pathways which 
explain the presence of both low IGF-I and testosterone levels and their relation to a higher 
mortality.  
 
The ongoing discovery of new biomarkers presents opportunities and challenges for 
biostaticians and clinicians to evaluate and judge these new biomarkers and to develop new 
risk models for a more individualized medical approach. Therefore we estimated the IDI to 
examine whether the prediction of all-cause mortality by a combination of both hormones is 
superior. In the present study, the estimates of IDI suggest that the addition of IGF-I and total 
testosterone to the model with established mortality risk factors did significantly improve the 
discriminatory property of the prediction model. However, the improvement was low.  
 
The aim of our study was to verify the previously described association between the 
combination of low hormone levels and all-cause mortality based on low IGF-I and total 
testosterone levels in large setting. The analysed studies were conducted in the same country 
with the same health care system and covered a wide age-range. However, both studies based 
on different backgrounds (primary care and population-based) which results in differences 
with respect to e.g. age, WHTR, and proportion of diabetes or increased blood pressure (Table 
A.2). One further strength was the use of the same assay in both studies to measure IGF-I 
levels. Limitations might have arisen from the single determination of IGF-I or total 
testosterone which was measured only at baseline. Additionally, hormone levels may vary 
because of individual fasting or the time of day in particular for total testosterone. Blood 
samples were taken between 07:00 a.m. and 04:00 p.m., however, a previous investigation in 
SHIP showed only minor differences in total testosterone levels between serum samples 
drawn before and after noon [32], therefore, this variation is expected to be minimal. 
Furthermore, different assay systems to determine total testosterone were used (SHIP: 
Siemens Immulite 2500, DETECT: Roche Diagnostics) and the assays were not cross-
checked between both studies. Therefore, low total testosterone levels were separately defined 
by percentiles in both studies. However, analyses using the overall 10th percentile to define 
low hormone levels confirmed our main results (Table A.3). A further limitation arise from 
the missing measurement of sex hormone-binding globulin, therefore no calculation of the 
free and bioavailable testosterone was possible. Moreover, the follow-up in our study, 
particularly in the DETECT study was rather short and less than 10% of all participants died 
during follow-up. Therefore we can only draw conclusions on early death and we do not 
know if our findings extend to longer-term follow-up. Furthermore, analyses with cause-
specific mortality would further clarify the relation between multiple anabolic deficiencies 
and mortality. Unfortunately due to the small number of subjects with both low IGF-I and 
testosterone levels and inferential the low number of death in this group analyses with cause-
specific mortality were not realisable.  
 
In conclusion, our results confirm former studies showing that multiple anabolic deficiencies 
have a higher impact on mortality than a single anabolic deficiency. Furthermore, the 
inclusion of both hormones, IGF-I and testosterone, did improve prediction models for all-
cause mortality including established risk markers in this study. Therefore our results suggest 
that assessment of more than one anabolic hormone as a biomarker improve the prediction of 
all-cause mortality in men in a population-based approach.  
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